Search results
Results from the WOW.Com Content Network
Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. [4] [5] It is not indicated for the preventive treatment of migraine. [6] Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist.
Cancer and Metastasis Reviews is a quarterly peer-reviewed medical review journal covering oncology and the development of new cancer treatments. It was established in 1982 and is published by Springer Science+Business Media .
The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years. [14] [15]
The Annual Review of Immunology is a peer-reviewed scientific journal published by Annual Reviews. It releases an annual volume of review articles relevant to the field of immunology . It was first published in 1983 with inaugural editor William E. Paul ; Paul remained editor for the journal's first thirty years.
These are the first class of preventive medications originally designed and approved for people with migraine. [27] Monoclonal means all the antibodies are made from the same genetic material, although different MABs may derive from different sources, e.g. from hamster ovarian cells, from yeast cells or from humanized cell cultures.
Medicinal Research Reviews is a bimonthly peer-reviewed scientific journal that publishes reviews on topics related to medicinal research. It is published by Wiley and was established in 1980. [ 1 ] The editor-in-chief is Amanda E. Hargrove ( Duke University ).
The Annual Review of Medicine is a peer-reviewed medical journal that publishes review articles about all aspects of medicine. It was established in 1950. It was established in 1950. Its longest-serving editors have been William P. Creger (1974–1993) and C. Thomas Caskey (2001–2019).
The Annual Review of Cancer Biology was first published in 2017, making it the 47th journal title published by Annual Reviews. [5] The stated goals of the journal were to cover the biology of tumor cells, the interaction between the tumor cells and host cells, cancer genomes, drugs for treating cancer, and the resistance of cancer to certain drugs. [6]